Korro Bio (KRRO) director-tied funds sell 28K shares on Aug. 19
Korro Bio (KRRO) director Jean Francois Formela reported indirect sales of 28,468 shares of common stock on August 19, 2026, by associated venture funds. The sales, totaling $399K, were made under a Rule 10b5-1 trading plan at a weighted average price of $14.00 per share. Formela disclaims beneficial ownership except for any pecuniary interest.
How this was made
The 30-second read
Why it matters
The transaction is a routine insider sell with limited material impact; investors should monitor for any larger subsequent disposals.
Market read
A small insider sell that may cause a modest, short‑term price dip but carries low trading relevance.
What to watch
Potential upcoming financing or dilution events not disclosed; the sale may hint at future capital needs.
Background
Form 4 filing reveals director‑tied venture funds sold shares via a pre‑arranged 10b5‑1 plan, disclosing indirect ownership and sale details.
Ticker impact
Director Jean Francois Formela disclosed indirect sale of 28,468 shares at $14 avg via Atlas funds under a Rule 10b5‑1 plan on Aug 19, 2026.
minor short‑term dip, limited to a few cents
Small insider sell under $1M typically signals limited conviction; market impact is expected to be minimal.
Market effects
None; biotech sector not materially affected by a single small insider transaction.
None; impact confined to KRRO shareholders.
None
Counterpoint
The sale could be a routine liquidity event unrelated to company fundamentals; investors may ignore it.
Key entities
- companyKorro Bio, Inc.
Biotech firm listed on NASDAQ under ticker KRRO.
- directorJean Francois Formela
Director of Korro Bio, associated with Atlas venture funds.


